Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Shares Outstanding (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Shares Outstanding for 5 consecutive years, with $62.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 2.53% to $62.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $62.6 million through Dec 2025, up 2.53% year-over-year, with the annual reading at $62.6 million for FY2025, 2.53% up from the prior year.
  • Shares Outstanding hit $62.6 million in Q4 2025 for Protagonist Therapeutics, roughly flat from $62.4 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $62.6 million in Q4 2025 to a low of $48.6 million in Q1 2022.
  • Historically, Shares Outstanding has averaged $57.2 million across 4 years, with a median of $58.6 million in 2024.
  • Biggest five-year swings in Shares Outstanding: rose 18.1% in 2023 and later grew 2.21% in 2024.
  • Year by year, Shares Outstanding stood at $49.2 million in 2022, then increased by 17.3% to $57.7 million in 2023, then increased by 5.76% to $61.0 million in 2024, then grew by 2.53% to $62.6 million in 2025.
  • Business Quant data shows Shares Outstanding for PTGX at $62.6 million in Q4 2025, $62.4 million in Q3 2025, and $62.1 million in Q2 2025.